Literature DB >> 35941192

Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Sjoukje J C van der Stegen1,2, Pieter L Lindenbergh1,2,3, Roseanna M Petrovic1,2, Hongyao Xie1,2, Mame P Diop1,2, Vera Alexeeva1,2, Yuzhe Shi1,2, Jorge Mansilla-Soto1,2, Mohamad Hamieh1,2, Justin Eyquem1,2,4, Annalisa Cabriolu1,2, Xiuyan Wang5, Ramzey Abujarour6, Tom Lee6, Raedun Clarke6, Bahram Valamehr6, Maria Themeli3, Isabelle Riviere5, Michel Sadelain7,8.   

Abstract

The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the generation of 'off-the-shelf' CAR T cells, but the in vitro differentiation of TiPS often yields T cells with suboptimal features. Here we show that the premature expression of the T-cell receptor (TCR) or a constitutively expressed CAR in TiPS promotes the acquisition of an innate phenotype, which can be averted by disabling the TCR and relying on the CAR to drive differentiation. Delaying CAR expression and calibrating its signalling strength in TiPS enabled the generation of human TCR- CD8αβ+ CAR T cells that perform similarly to CD8αβ+ CAR T cells from peripheral blood, achieving effective tumour control on systemic administration in a mouse model of leukaemia and without causing graft-versus-host disease. Driving T-cell maturation in TiPS in the absence of a TCR by taking advantage of a CAR may facilitate the large-scale development of potent allogeneic CD8αβ+ T cells for a broad range of immunotherapies.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35941192     DOI: 10.1038/s41551-022-00915-0

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   29.234


  63 in total

Review 1.  New cell sources for T cell engineering and adoptive immunotherapy.

Authors:  Maria Themeli; Isabelle Rivière; Michel Sadelain
Journal:  Cell Stem Cell       Date:  2015-04-02       Impact factor: 24.633

Review 2.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

3.  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.

Authors:  Reuben Benjamin; Charlotte Graham; Deborah Yallop; Agnieszka Jozwik; Oana C Mirci-Danicar; Giovanna Lucchini; Danielle Pinner; Nitin Jain; Hagop Kantarjian; Nicolas Boissel; Marcela V Maus; Matthew J Frigault; André Baruchel; Mohamad Mohty; Athos Gianella-Borradori; Florence Binlich; Svetlana Balandraud; Fabien Vitry; Elisabeth Thomas; Anne Philippe; Sylvain Fouliard; Sandra Dupouy; Ibtissam Marchiq; Maria Almena-Carrasco; Nicolas Ferry; Sylvain Arnould; Cyril Konto; Paul Veys; Waseem Qasim
Journal:  Lancet       Date:  2020-12-12       Impact factor: 79.321

Review 4.  Therapeutic T cell engineering.

Authors:  Michel Sadelain; Isabelle Rivière; Stanley Riddell
Journal:  Nature       Date:  2017-05-24       Impact factor: 49.962

5.  Autologous lymphapheresis for the production of chimeric antigen receptor T cells.

Authors:  Elizabeth S Allen; David F Stroncek; Jiaqiang Ren; Anne F Eder; Kamille A West; Terry J Fry; Daniel W Lee; Crystal L Mackall; Cathy Conry-Cantilena
Journal:  Transfusion       Date:  2017-02-24       Impact factor: 3.157

Review 6.  CAR T cells for infection, autoimmunity and allotransplantation.

Authors:  Colby R Maldini; Gavin I Ellis; James L Riley
Journal:  Nat Rev Immunol       Date:  2018-10       Impact factor: 53.106

Review 7.  'Off-the-shelf' allogeneic CAR T cells: development and challenges.

Authors:  S Depil; P Duchateau; S A Grupp; G Mufti; L Poirot
Journal:  Nat Rev Drug Discov       Date:  2020-01-03       Impact factor: 84.694

Review 8.  CAR T cells: Building on the CD19 paradigm.

Authors:  Anat Globerson Levin; Isabelle Rivière; Zelig Eshhar; Michel Sadelain
Journal:  Eur J Immunol       Date:  2021-08-02       Impact factor: 6.688

Review 9.  Clinical manufacturing of CAR T cells: foundation of a promising therapy.

Authors:  Xiuyan Wang; Isabelle Rivière
Journal:  Mol Ther Oncolytics       Date:  2016-06-15       Impact factor: 7.200

Review 10.  Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.

Authors:  Yuehong Chen; Jianhong Sun; Huan Liu; Geng Yin; Qibing Xie
Journal:  J Immunol Res       Date:  2019-12-31       Impact factor: 4.818

View more
  1 in total

1.  Integrating context for superior cancer prognosis.

Authors:  Guillaume Jaume; Andrew H Song; Faisal Mahmood
Journal:  Nat Biomed Eng       Date:  2022-08-18       Impact factor: 29.234

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.